Research progress on material composition, pre-clinical pharmacokinetic, and pharmacodynamic studies of Shengmai Injection
10.7501/j.issn.0253-2670.2020.20.030
- VernacularTitle: 生脉注射液物质组成, 临床前药动学和药效学的研究进展
- Author:
Bo-Hong ZHENG
1
Author Information
1. Medical College of Jiaxing University
- Publication Type:Journal Article
- Keywords:
Material composition;
Pharmacodynamics;
Pharmacokinetics;
Shengmai Injection;
TCM formula
- From:
Chinese Traditional and Herbal Drugs
2020;51(20):5360-5371
- CountryChina
- Language:Chinese
-
Abstract:
Shengmai Injection (SMI), is a traditional Chinese medicine (TCM) formula injection composed of Panax ginseng, Ophiopogon japonicas and Schisandra chinensis, which is widely used in clinic for the treatment of cardiovascular diseases as well as protecting against pulmonary disease and add-on therapy to cancer chemotherapy. In recent years, the pre-clinical basic research of SMI was widely performed. The studies, including chemical composition, in vivo process, and action mechanism and so on of SMI, helped to provide scientific foundation for revealing the material basis of formula. In this paper, the studies on material composition, pre-clinical pharmacokinetics and pharmacodynamics of this formula were summarized, so as to provide reference for the quality control, second development and rational clinical application of SMI.
